Israel - English - Ministry of Health

novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 0.25 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.

Israel - English - Ministry of Health

novartis israel ltd - siponimod as fumaric acid - film coated tablets - siponimod as fumaric acid 2 mg - siponimod - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include relapsing-remitting disease, and active secondary progressive disease, in adults.

European Union - English - EMA (European Medicines Agency)

novartis europharm limited  - siponimod fumaric acid - multiple sclerosis, relapsing-remitting - selective immunosuppressants - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms) with active disease evidenced by relapses or imaging features of inflammatory activity.

Canada - English - Health Canada

novartis pharmaceuticals canada inc - siponimod - tablet - 0.25mg - siponimod 0.25mg - immunomodulatory agents

Canada - English - Health Canada

novartis pharmaceuticals canada inc - siponimod - tablet - 2mg - siponimod 2mg - immunomodulatory agents

United States - English - NLM (National Library of Medicine)

novartis pharmaceuticals corporation - siponimod (unii: rr6p8l282i) (siponimod - unii:rr6p8l282i) - mayzent is indicated for the treatment of relapsing forms of multiple sclerosis (ms), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. mayzent is contraindicated in patients who have: - a cyp2c9*3/*3 genotype [see use in specific populations (8.6) and clinical pharmacology (12.5)] - in the last 6 months experienced myocardial infarction, unstable angina, stroke, tia, decompensated heart failure requiring hospitalization, or class iii or iv heart failure - presence of mobitz type ii second-degree, third-degree av block, or sick sinus syndrome, unless patient has a functioning pacemaker [see warnings and precautions (5.4)] pregnancy exposure registry there is a pregnancy exposure registry that monitors pregnancy outcomes in women exposed to mayzent during pregnancy. healthcare providers are encouraged to enroll pregnant patients, or pregnant women may register themselves in the mothertobaby pregnancy study in multiple sclerosis by calling

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - siponimod hemifumarate, quantity: 2.024 mg (equivalent: siponimod, qty 2 mg) - tablet, film coated - excipient ingredients: microcrystalline cellulose; xanthan gum; lactose monohydrate; colloidal anhydrous silica; glycerol dibehenate; polyvinyl alcohol; iron oxide red; lecithin; purified talc; crospovidone; titanium dioxide; iron oxide yellow - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms)

Australia - English - Department of Health (Therapeutic Goods Administration)

novartis pharmaceuticals australia pty ltd - siponimod hemifumarate, quantity: 0.278 mg (equivalent: siponimod, qty 0.25 mg) - tablet, film coated - excipient ingredients: iron oxide black; titanium dioxide; lactose monohydrate; lecithin; crospovidone; polyvinyl alcohol; purified talc; colloidal anhydrous silica; glycerol dibehenate; microcrystalline cellulose; iron oxide red; xanthan gum - mayzent is indicated for the treatment of adult patients with secondary progressive multiple sclerosis (spms)

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - siponimod fumaric acid -

Malaysia - English - NPRA (National Pharmaceutical Regulatory Agency, Bahagian Regulatori Farmasi Negara)

novartis corporation (malaysia) sdn. bhd. - siponimod fumaric acid -